Alpine Global Management LLC Purchases 50,000 Shares of Liquidia Co. (NASDAQ:LQDA)

Alpine Global Management LLC boosted its position in shares of Liquidia Co. (NASDAQ:LQDA) by 50.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 150,000 shares of the company’s stock after purchasing an additional 50,000 shares during the period. Alpine Global Management LLC’s holdings in Liquidia were worth $1,764,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in LQDA. LM Advisors LLC bought a new position in Liquidia during the 4th quarter worth about $25,948,000. Invesco Ltd. grew its holdings in shares of Liquidia by 2,675.0% in the 4th quarter. Invesco Ltd. now owns 700,171 shares of the company’s stock valued at $8,234,000 after acquiring an additional 674,940 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Liquidia by 1,484.5% in the 4th quarter. Janus Henderson Group PLC now owns 535,552 shares of the company’s stock valued at $6,293,000 after acquiring an additional 501,752 shares in the last quarter. Mirabella Financial Services LLP bought a new position in shares of Liquidia in the 4th quarter valued at about $5,880,000. Finally, Eversept Partners LP grew its holdings in shares of Liquidia by 314.1% in the 4th quarter. Eversept Partners LP now owns 571,305 shares of the company’s stock valued at $6,719,000 after acquiring an additional 433,356 shares in the last quarter. Institutional investors own 64.54% of the company’s stock.

Liquidia Stock Performance

Shares of NASDAQ:LQDA opened at $15.56 on Friday. Liquidia Co. has a 52-week low of $8.26 and a 52-week high of $19.41. The company has a market capitalization of $1.33 billion, a P/E ratio of -9.55 and a beta of 0.24. The company has a 50-day simple moving average of $14.73 and a 200 day simple moving average of $13.54.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The firm had revenue of $3.12 million during the quarter, compared to analyst estimates of $3.23 million. As a group, equities analysts forecast that Liquidia Co. will post -1.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on LQDA shares. Wall Street Zen upgraded Liquidia from a “sell” rating to a “hold” rating in a report on Thursday. Needham & Company LLC restated a “buy” rating and issued a $25.00 price objective on shares of Liquidia in a report on Wednesday. HC Wainwright restated a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a report on Monday, May 12th. Raymond James raised their price objective on Liquidia from $27.00 to $29.00 and gave the company a “strong-buy” rating in a report on Friday, May 9th. Finally, Scotiabank restated an “outperform” rating on shares of Liquidia in a report on Monday, May 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Liquidia has an average rating of “Moderate Buy” and an average target price of $25.56.

Insiders Place Their Bets

In other Liquidia news, CEO Roger Jeffs sold 14,130 shares of the firm’s stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $191,744.10. Following the completion of the sale, the chief executive officer now directly owns 1,006,420 shares in the company, valued at $13,657,119.40. This trade represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jason Adair sold 1,856 shares of the firm’s stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $25,185.92. Following the sale, the insider now owns 184,304 shares of the company’s stock, valued at $2,501,005.28. This trade represents a 1.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,138 shares of company stock worth $450,233 over the last three months. Insiders own 26.50% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).